Select Asset Management & Trust Acquires 2,200 Shares of Johnson & Johnson (NYSE:JNJ)

Select Asset Management & Trust increased its holdings in Johnson & Johnson (NYSE:JNJ) by 164.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,535 shares of the company’s stock after buying an additional 2,200 shares during the period. Select Asset Management & Trust’s holdings in Johnson & Johnson were worth $511,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Principal Financial Group Inc. lifted its holdings in Johnson & Johnson by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after purchasing an additional 329,473 shares in the last quarter. Invst LLC increased its position in shares of Johnson & Johnson by 394.0% during the third quarter. Invst LLC now owns 10,290 shares of the company’s stock valued at $1,668,000 after buying an additional 8,207 shares during the period. McIlrath & Eck LLC lifted its holdings in shares of Johnson & Johnson by 10.7% in the third quarter. McIlrath & Eck LLC now owns 2,892 shares of the company’s stock worth $469,000 after buying an additional 279 shares in the last quarter. Passumpsic Savings Bank bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $262,000. Finally, Te Ahumairangi Investment Management Ltd increased its holdings in Johnson & Johnson by 10.1% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company’s stock worth $8,180,000 after acquiring an additional 4,640 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on JNJ. Barclays reduced their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday. Morgan Stanley boosted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 16th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Raymond James dropped their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $171.82.

Johnson & Johnson Price Performance

JNJ opened at $157.42 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock’s 50 day simple moving average is $159.49 and its 200 day simple moving average is $154.95. The firm has a market cap of $379.37 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.30%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.